The present invention concerns a method of treating peanut allergy in a subject, or a population of subjects, the method comprising administering to said subject or population of subjects a peanut allergen by an oral immunotherapy (OIT) regimen comprising a dose escalation phase in which the peanut allergen is administered in a dose which is increased in increments from an initial dose of the allergen equivalent of 5 mg peanut protein or less to a dose of the allergen equivalent of 200 mg peanut protein or more within 4 to 9 weeks from the administration of the initial dose. The treatment reduces the length of the build-up phase in peanut OIT methods and improves the likelihood or odds of the subject achieving sustained unresponsiveness.

The present invention concerns a method of treating peanut allergy in a subject, or a population of subjects, the method comprising administering to said subject or population of subjects a peanut allergen by an oral immunotherapy (OIT) regimen comprising a dose escalation phase in which the peanut allergen is administered in a dose which is increased in increments from an initial dose of the allergen equivalent of 5 mg peanut protein or less to a dose of the allergen equivalent of 200 mg peanut protein or more within 4 to 9 weeks from the administration of the initial dose. The treatment reduces the length of the build-up phase in peanut OIT methods and improves the likelihood or odds of the subject achieving sustained unresponsiveness.

In aspects, a cannabis extract enriched in polyphenolic compounds is provided herein. Also provided herein is a method for enriching a composition with polyphenolic compounds as well as compositions made by the method. Various cosmetic and pharmaceutical products, methods, and uses are provided herein as well as natural health products.

In aspects, a cannabis extract enriched in polyphenolic compounds is provided herein. Also provided herein is a method for enriching a composition with polyphenolic compounds as well as compositions made by the method. Various cosmetic and pharmaceutical products, methods, and uses are provided herein as well as natural health products.

Disclosed is the use of a checkpoint kinase (CHK) inhibitor in combination with i) a poly(ADP)-ribose polymerase inhibitor, and optionally ii) a chemotherapeutic agent such as gemcitabine, in cancer treatment.

Disclosed is the use of a checkpoint kinase (CHK) inhibitor in combination with i) a poly(ADP)-ribose polymerase inhibitor, and optionally ii) a chemotherapeutic agent such as gemcitabine, in cancer treatment.

The present invention relates to a composition, comprising: IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α, for promoting immunomodulatory activity and inflammation-modulating ability of stem cells, and a method for preparing stem cells having improved immunomodulatory activity and inflammation-modulating ability by using same. When treated with IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α according to the present invention, stem cells are induced to increase IFN-γ inhibition, inducible costimulatory ligand (ICOSL) expression, indoleamine 2,3-dioxygenase (IDO) expression, and Galectin 1 expression, and thus can find various applications in a variety of immune disease treatment fields using stem cells.

The present invention relates to a composition, comprising: IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α, for promoting immunomodulatory activity and inflammation-modulating ability of stem cells, and a method for preparing stem cells having improved immunomodulatory activity and inflammation-modulating ability by using same. When treated with IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α according to the present invention, stem cells are induced to increase IFN-γ inhibition, inducible costimulatory ligand (ICOSL) expression, indoleamine 2,3-dioxygenase (IDO) expression, and Galectin 1 expression, and thus can find various applications in a variety of immune disease treatment fields using stem cells.

Cannabinoids are used to treat diseases or disorders treatable by an activator of the A.sub.3 adenosine receptor (A.sub.3AR). The cannabinoid effect is exerted through the A3AR. The cannabinoids may be selected from natural, phytocannabinoids, synthetic derivatives of phytocannabinoids, extracts of cannabis plant, and others.

Cannabinoids are used to treat diseases or disorders treatable by an activator of the A.sub.3 adenosine receptor (A.sub.3AR). The cannabinoid effect is exerted through the A3AR. The cannabinoids may be selected from natural, phytocannabinoids, synthetic derivatives of phytocannabinoids, extracts of cannabis plant, and others.